| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
Serine-threonine phosphatases (inhibitor). beta-Glycerophosphate disodium salt hydrate acts as a phosphate group donor and interacts with various enzymes by binding to the active site of phosphatases, preventing the dephosphorylation of target proteins. It also serves as a substrate in enzymatic assays for phosphatases and kinases.
|
|---|---|
| ln Vitro |
beta-Glycerophosphate disodium salt hydrate is a phosphatase inhibitor that blocks the dephosphorylation of target proteins. As a phosphate source for hydroxyapatite, it promotes osteoblast differentiation through the phosphorylation of extracellular signal-related kinases (ERK1/2). It accelerates calcification in vascular smooth muscle cells and is essential for inducing and maintaining osteoblast differentiation.
|
| ln Vivo |
In vivo, beta-Glycerophosphate disodium salt hydrate is absorbed and utilized by the body for bone mineralization, enzyme function, and cellular metabolism. When used in animal models, it supports the formation of mineralized bone matrix and is essential for skeletal development studies. Its primary role is as a nutritional supplement or a component of tissue engineering scaffolds.
|
| Enzyme Assay |
For non-cellular assays, beta-Glycerophosphate disodium salt hydrate is dissolved in assay buffer at concentrations ranging from 1-50 mM. Phosphatase enzymes are incubated with the compound, and phosphatase activity is measured using a colorimetric or fluorogenic phosphate substrate. The inhibition of phosphate release is quantified by absorbance or fluorescence to assess inhibitory potency.
|
| Cell Assay |
For cell culture experiments, beta-Glycerophosphate disodium salt hydrate is added to osteogenic differentiation media at a final concentration of 5-10 mM. Cells are cultured for 7-21 days, and mineralization is assessed by Alizarin Red S or Von Kossa staining. Alkaline phosphatase activity is measured using a p-nitrophenyl phosphate (pNPP) substrate, and cell viability is assessed using MTT assays.
|
| Animal Protocol |
For in vivo nutritional studies, beta-Glycerophosphate disodium salt hydrate is administered orally as a dietary supplement or intravenously via total parenteral nutrition (TPN) solutions. Dosages are calculated based on calcium and phosphorus requirements for bone health. Blood calcium and phosphorus levels are monitored, and bone density is assessed by micro-CT or dual-energy X-ray absorptiometry (DXA) in long-term studies.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Peak serum phosphate concentrations are reached within 4 hours. The generated inorganic phosphate is excreted in the urine. A small amount of glycerophosphate may be excreted unchanged in the urine. Metabolism/Metabolites Glycerophosphate is hydrolyzed to produce inorganic phosphate. The extent of this reaction depends on the activity of serum alkaline phosphatase. Biological Half-Life The elimination half-life of inorganic phosphate is 2.06 hours. As a nutrient supplement, beta-Glycerophosphate disodium salt hydrate has well-established pharmacokinetics. Orally administered phosphate is absorbed in the small intestine via sodium-dependent phosphate transporters. Excretion occurs primarily through feces (unabsorbed) and urine (absorbed excess). Intravenous administration via TPN bypasses absorption and distributes directly to tissues. |
| Toxicity/Toxicokinetics |
beta-Glycerophosphate disodium salt hydrate is generally recognized as safe (GRAS) when used as a food additive or nutritional supplement. TPN formulations containing this compound are clinically used in patients requiring parenteral nutrition with a well-established safety profile. Overdose may lead to hyperphosphatemia, with potential renal and cardiovascular complications.
|
| References |
|
| Additional Infomation |
Sodium glycerophosphate is one of several glycerophosphates. Clinically, it is used to treat or prevent hypophosphatemia. Glycerophosphate is hydrolyzed in vivo to inorganic phosphates and glycerol. The extent of this reaction depends on the activity of serum alkaline phosphatase. Sodium glycerophosphate is the sodium salt form of an organic phosphate compound that provides the phosphates required for nutrition. Furthermore, sodium glycerophosphate can be used as a phosphate diluent when the body is contaminated with the beta-ray radioisotope phosphate P-32 (P-32), as P-32 competes with phosphate for absorption. When large doses of sodium glycerophosphate are administered, P-32 absorption can be inhibited or minimized. See also: Anhydrous sodium glycerophosphate (note moved to). Drug Indications Sodium glycerophosphate is indicated as a phosphate source in total parenteral nutrition. It is used in combination with amino acids, glucose, lipid emulsions, and other electrolytes. FDA Label Mechanism of Action Sodium glycerophosphate is used as a donor of inorganic phosphates. For information on the role of phosphates in the body, see [DB09413].
Pharmacodynamics Sodium glycerophosphate provides inorganic phosphates through hydrolysis. beta-Glycerophosphate disodium salt hydrate (CAS: 154804-51-0) has a molecular formula of C3H7Na2O6P and a molecular weight of 216.04. It is a bioactive endogenous metabolite and is often used in combination with ascorbic acid and dexamethasone to promote osteogenic differentiation of mesenchymal stem cells. It is not a drug but a research reagent and food additive. |
| Molecular Formula |
C3H7O6PNA2.XH2O
|
|---|---|
| Molecular Weight |
216.0374
|
| Exact Mass |
233.988
|
| CAS # |
154804-51-0
|
| PubChem CID |
22251426
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
102～104 ℃
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
117
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C(C[O-])OP(=O)(O)O)[O-].O.[Na+].[Na+]
|
| InChi Key |
OFNNKPAERNWEDD-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C3H9O6P.2Na.H2O/c4-1-3(5)2-9-10(6,7)8;;;/h3-5H,1-2H2,(H2,6,7,8);;;1H2/q;2*+1;/p-2
|
| Chemical Name |
disodium;2,3-dihydroxypropyl phosphate;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6288 mL | 23.1439 mL | 46.2877 mL | |
| 5 mM | 0.9258 mL | 4.6288 mL | 9.2575 mL | |
| 10 mM | 0.4629 mL | 2.3144 mL | 4.6288 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
